European Growth Companies With High Insider Ownership August 2026
As European markets show resilience with the STOXX Europe 600 Index gaining momentum, investor sentiment is buoyed by robust earnings and a firmer risk appetite despite ongoing geopolitical uncertainties. In such an environment, growth companies with high insider ownership can offer unique insights into potential investment opportunities, as insiders often have a deep understanding of their company's prospects and are more likely to align their interests with shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 61.1% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Envipco Holding (ENXTAM:ENVI) | 15.4% | 53.2% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 73.9% |
| CD Projekt (WSE:CDR) | 35.2% | 39% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.8% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
Let's explore several standout options from the results in the screener.
Vusion (ENXTPA:VU)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vusion S.A. provides digitalization solutions for commerce across various regions including France, Europe, the Middle East, Africa, Asia, and the Americas with a market cap of €2.17 billion.
Operations: The company's revenue is primarily derived from installing and maintaining electronic shelf labels, totaling €1.47 billion.
Insider Ownership: 12.8%
Vusion's growth trajectory is supported by strategic partnerships, including the expansion with JYSK and a major deployment for Gratis in Turkey. These moves enhance its market presence and operational capabilities, leveraging cloud solutions for scalability. Despite recent volatility in share price, Vusion trades below fair value estimates and analysts expect a 58.2% rise in stock price. Forecasted revenue growth of 6.8% annually outpaces the French market, reinforcing its potential as a growth-oriented company with high insider ownership influence on strategy execution.
- Get an in-depth perspective on Vusion's performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Vusion's share price might be on the cheaper side.
Lime Technologies (OM:LIME)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lime Technologies AB (publ) provides software as a service (SaaS) based customer relationship management (CRM) solutions in the Nordic region, with a market cap of SEK3.04 billion.
Operations: The company's revenue segment includes selling and implementing CRM software systems, generating SEK781.17 million.
Insider Ownership: 10.7%
Lime Technologies shows promising growth potential with recent earnings increasing by 20% over the past year and projections indicating a 16.1% annual earnings growth, outpacing the Swedish market. The company's revenue is also expected to grow faster than the market at 8.7% annually. Insider activity reflects confidence, with substantial insider buying in recent months and no significant selling. Trading below fair value estimates, analysts anticipate a stock price rise of 33.3%.
- Click here and access our complete growth analysis report to understand the dynamics of Lime Technologies.
- Upon reviewing our latest valuation report, Lime Technologies' share price might be too pessimistic.
Newron Pharmaceuticals (SWX:NWRN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on discovering and developing novel therapies for central and peripheral nervous system diseases in Italy and the United States, with a market cap of CHF254.25 million.
Operations: The company generates revenue primarily from the research and development of pharmaceutical drugs, amounting to €19.13 million.
Insider Ownership: 10.1%
Newron Pharmaceuticals is poised for significant growth, with revenue expected to increase by 38.2% annually, surpassing the Swiss market's average. The company is forecast to achieve profitability within three years, indicating robust potential compared to market averages. Despite trading at a substantial discount to its estimated fair value, the stock has experienced high volatility recently. No recent insider buying or selling activity has been reported over the past three months.
- Unlock comprehensive insights into our analysis of Newron Pharmaceuticals stock in this growth report.
- Our valuation report here indicates Newron Pharmaceuticals may be undervalued.
Key Takeaways
- Take a closer look at our Fast Growing European Companies With High Insider Ownership list of 220 companies by clicking here.
- Curious About Other Options? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com